Twentyeight-Seven Therapeutics
Twentyeight-Seven Therapeutics develops microRNAs and small molecules to target proteins involved in cancer progression.
Founded
2016Twentyeight-Seven Therapeutics develops microRNAs and small molecules to target proteins involved in cancer progression.
Twentyeight-Seven Therapeutics, founded with a mission to develop innovative therapies for serious diseases, focuses on the modulation of microRNAs and small molecules to target regulatory proteins involved in cancer progression. Their core vision is to restore cellular balance by targeting nucleic acid processing and signaling, which are crucial for maintaining cellular homeostasis. The company aims to create groundbreaking treatments by exploring new therapeutic pathways that address the initiation, progression, and metastasis of cancer.
Notable figures affiliated with Twentyeight-Seven Therapeutics include leading scientists and industry experts who contribute to the company's pioneering research. The startup has attracted significant investment from prominent venture capital firms, underscoring its potential impact in the biotech industry. Key achievements include the development of proprietary technologies that modulate miRNA levels, positioning the company as a leader in RNA-based cancer therapies. Twentyeight-Seven Therapeutics continues to make strides in transforming cancer treatment, offering hope for more effective and targeted therapies.
Companies similar to Twentyeight-Seven Therapeutics include Nextrna Therapeutics, 2seventy bio, Dual Therapeutics and Celsius Therapeutics.
Twentyeight-Seven Therapeutics was founded in 2016.
Twentyeight-Seven Therapeutics' headquarters is located in Cambridge, MA, US.
Twentyeight-Seven Therapeutics' most recent funding round was for $15M (USD) in May 2019.
As of May 9, 2019, Twentyeight-Seven Therapeutics has raised a total of $80M (USD).
Twentyeight-Seven Therapeutics has 35 employees as of Feb 4, 2024.
Dual Therapeutics
